Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSA-Based Vaccine in Localized Prostate Cancer Receiving Standard Radiotherapy
NCT00005916Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2000
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rilimogene galvacirepvec, PROSTVAC-F/TRICOM and recombinant vaccinia-B7.1 vaccine in prostate cancer (PCa) (3 arms), sponsored by National Cancer Institute. Primary endpoint: Immunologic response as measured by in vitro analysis of peripheral blood cells. Started Jun 2000; status: completed.
02
Drugs
rilimogene galvacirepvecPROSTVAC-F/TRICOMrecombinant vaccinia-B7.1 vaccine
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00005916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005916.